My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Teva Pharmaceutical Industries Limited (TEVA) — RQD Stock Rating Cockpit

$38.53 -8.76% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $37.85

Teva Pharmaceutical Industries Limited (TEVA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $44.96B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TEVA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TEVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, Teva Pharmaceutical Industries Limited (NYSE: TEVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $38.53 (-8.76% 1D, market cap $44.96B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, TEVA ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TEVA compare to ONC and RPRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TEVA carries a Roarable D+ (53/100 RQD), trailing P/E of 34.3x, gross margin of 51.8%, and ROIC of 9.4%. By comparison, ONC (BeOne Medicines Ltd.) holds a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $45.66B) and RPRX (Royalty Pharma plc (Class A)) posts a B grade (74/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.84B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TEVA?
▼

Per TEVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818686), Teva Pharmaceutical Industries Limited generated $17.26B in revenue (+4.3% YoY), $1.41B in net income, and $872.4M in free cash flow against $40.75B in total assets and $14.78B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 TEVA TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $TEVA, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $TEVA R/R 2.2 : 1 • RQD 53/100 (D+)
$TEVA
Spot $38.53
1. GET IN (ENTRY)
$38.30–$38.72
2. HARD STOP (SUP)
$36.53 (-5.2%)
3. GET OUT (T1/T2)
$41.03 / $42.96
STOP-LOSS FLOOR (SUP $36.53): Hard stop sits 5.2% below spot to cap downside below key institutional support. If $TEVA closes a daily candle below $36.53, step aside.
PROFIT TARGETS (RES $41.03 / $42.96): Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $TEVA sheet + Today's Top 3 Trades emailed free? Paper Trade $TEVA →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $TEVA Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $37.85 (-1.77%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 5.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk D+
Cash (9)Whales (10)SEC (12)Macro (10)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$47 Bull$38 Base$29 Bear
📬 FREE TEVA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TEVA)Realized 20D OHLCV Swing Band: ±5.1%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY TEVA SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)

Altman Z-Score 1.02 (DISTRESS RISK (<1.8)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Disciplined Float (-0.04% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)

Capital intensity & 12.5% operating margin leave 11 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$41.77+1.5% Next Q
Q2 (-2Q)
58
Grade C$42.39+5.1% Next Q
Q3 (-1Q)
56
Grade C$44.54-13.5% Next Q
Current
53
Grade D+$38.53-0.9% Hist 90D α
Trajectory: C (61) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TEVA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TEVA currently carries a cautious 53/100 (D+) rating due to Cash Engine Quality (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($40.95) and Max Pain ($40.46) forces dealer call-delta covering toward $46.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.04% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TEVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TEVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
3430 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.02>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE67% OF RANGE
L: $26$38.53H: $45
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on TEVA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

9.4% ROIC with 51.8% gross margin and 1.81% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 1.02 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (53)

22/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like TEVA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TEVA)

  • ✓Walkthrough of TEVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TEVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.33%▼ SUPPORT BREAKDOWN
2026-11-22O $42.23H $42.23L $38.53C $38.53VOL 10.39M
$45.74$40.77$35.79$30.82$25.85RES $44.97SUP $41.91$38.532026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE NARROW ECONOMIC MOAT (ROIC 9.4% vs WACC 6.4%)

TEVA Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $25.70 vs Spot $38.53
MODESTLY OVERVALUED (-49.9%)
Undervalued Zone (< $22) Fair Value Corridor ($22–$30) Overvalued (> $30)
$39
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own TEVA Growth & WACC Assumptions

YOUR DCF TARGET
$35.48
5-Yr Annual FCF Growth Rate: 9.2%
Discount Rate (WACC Hurdle): 6.4%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: -49.9% vs $38.53 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TEVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
26.5%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TEVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TEVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TEVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TEVA)

Health Care Rank #200 of 1015 ⚔️ ONC vs TEVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TEVA vs. ONC, RPRX, ZTS, GMAB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Teva Pharmaceutical Industries Limited (TEVA) ranks #200 by composite RQD confidence (53/100, grade D+) and #41 by equity capitalization ($44.96B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with TEVA at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TEVA ACTIVE
Teva Pharmaceutical Industries Limited
D+ 53/100 34.3x 51.8% 9.4% -8.76% $44.96B Benchmark Subject
ONC
BeOne Medicines Ltd.
B- 71/100 147.2x 87.5% 10.5% -0.97% $45.66B /onc-vs-teva →
RPRX
Royalty Pharma plc (Class A)
B 74/100 49.2x — 7.0% -1.38% $38.84B /rprx-vs-teva →
ZTS
Zoetis Inc.
C 65/100 12.2x 71.8% 25.7% -5.57% $32.83B /zts-vs-teva →
GMAB
Genmab A/S ADS
B- 70/100 32.8x — 9.9% +0.75% $32.05B /gmab-vs-teva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818686 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Teva Pharmaceutical Industries Limited (TEVA) reported GAAP revenue of $17.26B (+4.3% vs. FY2024 revenue of $16.54B , and +8.9% cumulative change since FY2023) , GAAP net income of $1.41B, operating cash flow of $1.65B, and free cash flow of $872.4M (+73.6% YoY). On the balance sheet, TEVA closed FY2025 with $40.75B in total assets against $14.78B in total debt (Altman Z-Score: 1.02, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $17.26B $1.41B $1.65B $872.4M $40.75B $14.78B
FY2024 (FY) 2024-12-31 $16.54B -$1.64B $1.25B $502.5M $39.33B $15.12B
FY2023 (FY) 2023-12-31 $15.85B -$559.0M $1.37B $654.9M $26.58B $6.22B

3. TEVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TEVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Teva Pharmaceutical Industries Limited (NYSE: TEVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $38.53 (-8.76% 1D, market cap $44.96B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, TEVA ranks #200 in composite RQD confidence.

How does TEVA compare to ONC and RPRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TEVA carries a Roarable D+ (53/100 RQD), trailing P/E of 34.3x, gross margin of 51.8%, and ROIC of 9.4%. By comparison, ONC (BeOne Medicines Ltd.) holds a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $45.66B) and RPRX (Royalty Pharma plc (Class A)) posts a B grade (74/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.84B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TEVA?

Per TEVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818686), Teva Pharmaceutical Industries Limited generated $17.26B in revenue (+4.3% YoY), $1.41B in net income, and $872.4M in free cash flow against $40.75B in total assets and $14.78B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TEVA trading relative to its 50-day, 200-day, and 52-week technical levels?

TEVA last traded at $38.53 (-8.76% on volume of 10,385,081 shares), positioning the stock -5.91% below its 50-day simple moving average ($40.95) and +8.69% above its 200-day simple moving average ($35.45). Across its 52-week range of $26.39 to $44.54, TEVA sits at the 66.9% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±5.1% ($36.56 to $40.50).

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

TEVA — Teva Pharmaceutical Industries Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Teva Pharmaceutical Industries Limited (TEVA) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $38.53 (-8.76% 1D, market capitalization $44.96B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 9.4%, gross margin of 51.8%, operating margin of 12.5%, and free cash flow yield of 1.81%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.02, Piotroski F-Score of 8/9, and Debt/Equity of 1.74x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Teva Pharmaceutical Industries Limited is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a US-listed pharmaceutical company. Per the news wire, the company is described as transitioning from generics toward higher-margin branded drugs, and recent FDA approval of a monthly schizophrenia injection (Weltruza) is reported.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Teva Pharmaceutical Industries Limited (TEVA) reported $17.26B in annual revenue (up from $16.54B in FY2024, +4.3% YoY) and $1.41B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.85B revenue, -$559.0M net income) through FY2025, TEVA scaled operating cash flow to $1.65B and free cash flow to $872.4M, backed by $40.75B in total assets against $14.78B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.81% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $26.39 – $44.54 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 34.3x trailing P/E and 20.8x EV/EBITDA against 12.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks beyond the sector classification (Health Care / Biotechnology: Pharmaceutical Preparations). A prospective investor should note that the leverage figures (Debt/Equity 1.74; debt of $14.

  • Key Question #1: Can TEVA sustain or expand its 12.5% operating margin and 9.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $17.26B and free cash flow of $872.4M, how will capital allocation balance growth reinvestment against $14.78B in total debt?
  • Key Question #3: How sensitive is TEVA's 31.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TEVA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Teva Pharmaceutical Industries Limited (TEVA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TEVA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TEVA Bull vs. Bear Conversation Board — What's Your Call at $38.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TEVA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TEVA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $54.30 (+29.0%)
📌 Pinned Debate

Institutional accumulation (Whale pillar 18/20) and a reported swing to $1.41B net income in FY 2025, plus the Weltruza FDA approval,

The street is overcomplicating Teva Pharmaceutical Industries Limited (TEVA). Institutional accumulation (Whale pillar 18/20) and a reported swing to $1.41B net income in FY 2025, plus the Weltruza FDA approval, support the momentum case.. With an RQD score of 61/100 (C-) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $45.46.

RetailWhale_TX 🐂 BULL

Both sides have a point here — TEVA's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $36.20 (-14.0%)
Spot @ $42.09

A 34.3x trailing P/E, 1.81% FCF yield, Altman Z of 1.02, and Debt/Equity of 1.74 leave little valuation or balance-sheet cushion.

Careful chasing TEVA at $42.09. A 34.3x trailing P/E, 1.81% FCF yield, Altman Z of 1.02, and Debt/Equity of 1.74 leave little valuation or balance-sheet cushion.. Gross margin is 51.8%, but operating margin is 12.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $36.20 on multiple compression.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE